Summary of Omega-3 Fatty Acids
August 19th, 2026
Commonly known as “brain food”, omega-3 fatty acids (eg, EPA/DHA) are known as a healthy source of nutrition for the human brain as they serve as structural building blocks for neuronal membranes. Omega-3’s are also potent anti-inflammatory agents that aid in the upregulation of brain-derived neurotrophic factor (BDNF)— a critical protein required to heal mental disease.
Human synthesis of EPA/DHA is inefficient, so human brain levels depend heavily on dietary intake. Fortunately, omega-3 fatty acids are readily available as an over-the-counter medication which has good evidence as an adjunct treatment for depression, anxiety, and/or nicotine cessation dosed at ~1500-2000mg daily (with EPA >1000mg/day).
For most patients, risks are limited to minor GI/taste effects (“fishy taste”). However, caution should be taken for patients are at significant risk for development of atrial fibrillation (very small increase at ≥4000 mg/day) and in patients who are on anti-coagulation. However, the FDA has stated that fish oil at <3000mg/day is unlikely to cause any significant bleeding. Of note, DHA products may modestly raise LDL-C.
If you’d like to purchase omega-3 fatty acids, please visit the affiliate link below.
This product linked is dosed at 1780mg per capsule (with 1300mg EPA), therefore 1 capsule daily would be sufficient per dosing guidelines.
As a disclaimer, qualified purchases will go towards to an Amazon Associate account which in turn helps to keep this website going. Thank you!
affiliate link
How do Omega-3’s help our body?
The leading theories fall into four categories: membrane/structural, neurotransmission, anti-inflammatory/pro-resolution, and neurotrophic/neuroplasticity effects.
Membrane structure and fluidity (structural theory): DHA is the predominant omega-3 in neuronal and glial cell membranes, concentrated in gray matter and synapses, earning it the label "brain food." Human synthesis (de novo) of DHA/EPA from precursors is inefficient, so human brain levels depend heavily on dietary intake. Incorporation of DHA into phospholipids increases membrane fluidity, which in turn modulates the conformation and activity of membrane-embedded proteins—such as receptors, ion channels, and membrane-bound enzymes—thereby improving the efficiency of neurotransmission.
Neurotransmission: both DHA and EPA regulate neurotransmitter release and postsynaptic receptor binding. Omega-3–deficient diets are associated with reduced receptor density and disrupted signaling in serotonergic, dopaminergic, and adrenergic systems—systems central to mood regulation.
Anti-inflammatory and pro-resolution effects (specialized pro-resolving mediators): EPA and DHA are enzymatically converted (via lipoxygenase, cyclooxygenase, and CYP450 pathways) into specialized pro-resolving lipid mediators—resolvins (E- and D-series), protectins/neuroprotectin D1, and maresins—that actively resolve inflammation, reduce oxidative stress, and promote clearance of apoptotic cells and debris. At the cellular level, omega-3s shift microglia from a pro-inflammatory (M1) toward an anti-inflammatory (M2) phenotype and suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), partly through SIRT1-mediated inhibition of NF-κB signaling. Because neuroinflammation and elevated cytokines are implicated in depression and neurodegeneration, this pathway links omega-3s to both mood and cognitive outcomes. This is arguably the most mechanistically developed theory.
Neurotrophic support and neuroplasticity: omega-3s upregulate brain-derived neurotrophic factor (BDNF) which is one of the most important proteins in the brain that helps to promote neurogenesis, synaptic plasticity, and cerebral perfusion (via vasodilation). Increased expression of BDNF is thought to be one of the most critical factors to help address psychiatric illnesses across the board. DHA also supports myelination and synaptic pruning during development, and DHA deficiency in animal models downregulates plasticity markers (Egr-1, Arc, BDNF) and produces anxiety/depression-like and memory-impairment phenotypes that are reversible with repletion.
What dose should I use for Omega-3?
It is recommended that a high-EPA formulation (eg, EPA ≥60% of EPA+DHA) with a total dose of omega-3 fatty acids of 1500–2000 mg (with ~1000mg EPA) is taken daily as an adjunct treatment formood, anxiety and/or tobacco cessation.
What is the evidence for Omega-3?
For mood
Omega-3s (particularly EPA-predominant formulations) show a modest, evidence-supported benefit for depressive symptoms in people with existing depression. However, effects appear to be dose and composition-dependent with EPA content being a key driver. The largest dose-response meta-analysis (67 RCTs) found that each 1 g/day of omega-3 significantly improved depressive symptoms, with a larger effect in patients with existing depression and a U-shaped curve peaking at ~1.5 g/day; supplementation raised remission by ~19 per 100 (low-certainty) but did not prevent depression in the general population (moderate-certainty).
A meta-analysis of 10 RCTs found significant reductions in depression severity only when EPA constituted ≥60% of total EPA+DHA and doses were ≥1 g/day but <2 g/day; doses ≥2 g/day and DHA-predominant products were not effective.
CANMAT recommends omega-3 as a second-line monotherapy for mild-to-moderate MDD or adjunct for moderate-to-severe MDD, and ISNPR endorses it for prevention in high-risk adults. In contrast, the VA/DoD MDD guideline found no significant overall benefit and declined to recommend EPA over validated treatments. [5-6]
The 2021 Cochrane review concluded only a small-to-modest, non-clinically important benefit with low-to-very-low certainty, likely biased toward a positive finding.
A meta-analysis found adjunctive omega-3 improved bipolar depression (effect size 0.34) but not mania. However, the VA/DoD bipolar guideline and a 52-week prophylactic RCT found no significant benefit for depressive or manic symptoms, reflecting inconsistent data.
For anxiety
The evidence is genuinely mixed. A dose-response meta-analysis (23 trials, 2,189 patients) found a moderate reduction in anxiety symptoms, greatest at 2 g/day, but the certainty is low.
An earlier JAMA Network Open meta-analysis (19 trials) found omega-3 associated with improved anxiety symptoms, with stronger effects in clinical than subclinical populations.
Counterbalancing this, a large NUGAG/WHO meta-analysis (31 trials, >41,000 participants) concluded long-chain omega-3 probably has little or no effect on preventing depression or anxiety symptoms (moderate quality).
Evidence in youth (14–24) appears to be inconclusive.
For nicotine cessation
Two small placebo-controlled RCTs suggest omega-3 (roughly 0.9–2.7 g EPA + 0.6–2 g DHA daily) reduces cigarette craving and consumption over 1–3 months, but no large trials confirm it improves long-term quit rates. Omega-3 fatty acids are a reasonable, safe adjunct (but not a substitute) in addition to first-line therapies (varenicline, NRT, bupropion) plus behavioral support.
Pilot RCT (n=48 regular smokers). High-dose omega-3 (2710 mg EPA + 2040 mg DHA/day for 1 month) produced a significant decrease in self-reported daily smoking and in cue-induced tobacco craving versus placebo. Notably, craving did not return to baseline in the month after discontinuation. This was the first trial to test PUFA supplementation on tobacco craving; the authors called for larger studies.
RCT (n=54 heavy smokers, ≥20 cig/day). Fish-oil omega-3 (900 mg EPA + 600 mg DHA/day for 3 months) yielded significantly greater reductions in nicotine dependence, cigarette craving, and cigarettes smoked per day versus placebo, with the between-group difference widening over time. It also lowered oxidative stress markers (total oxidant status, oxidative stress index).
Summary
For a patient with existing clinical depression and/or anxiety, an EPA-predominant product (EPA ≥60% of total at >1000mg EPA daily) is the best-supported regimen as an adjunct; benefit for prevention in non-depressed individuals is not established. For nicotine cessation, omega-3 fatty acids are also a reasonable and safe adjunct in addition to first-line therapies (varenicline, NRT, bupropion) plus behavioral support.
What are side effects and/or precautions of Omega-3?
Omega-3 fatty acids are generally well tolerated, with side effects occurring in fewer than 5% of users and no definite serious adverse events attributable to them in a meta-analysis of 90 RCTs. The most important risks are the increased incidence of atrial fibrillation seen with high-dose prescription products, a modest bleeding-tendency signal, GI/taste effects, and an LDL-C rise with DHA-containing formulations.
Atrial fibrillation (low but considerable likelihood): high-dose prescription omega-3s significantly increased new-onset AF in two large trials: REDUCE-IT (icosapent ethyl 4 g/day) showed 5.3% vs 3.9% (p=0.004), and STRENGTH showed 2.2% vs 1.3% (p<0.001). The 2026 ACC/AHA dyslipidemia guideline lists new-onset atrial fibrillation/flutter as a recognized effect of this drug class.
Bleeding (low likelihood):omega-3s have antiplatelet and membrane-fluidity effects that can prolong bleeding time. The overall signal is small: a meta-analysis of 120,643 patients across 11 RCTs found no overall increase in bleeding (RR 1.09; 95% CI 0.91–1.31), and no increase in hemorrhagic stroke, intracranial, or GI bleeding. However, high-dose purified EPA conferred a ~50% relative but only ~0.6% absolute increase in bleeding risk, dose-dependent. The FDA considers intakes up to 3 g/day unlikely to cause significant bleeding; older reviews found no clinically significant bleeding up to 7 g/day even with antiplatelets or warfarin. Caution is still advised in patients on anticoagulants/antiplatelets or before surgery.
Gastrointestinal and taste (common): the most common effects are belching/eructation, nausea, dysgeusia ("fishy taste"), heartburn, and diarrhea/loose stools (worse at higher doses). The meta-analysis found significantly higher odds of diarrhea (OR 1.26), dysgeusia (OR 3.48), and slightly more withdrawals due to side effects.
Lipid effect (common): DHA-containing products (omega-3-acid ethyl esters) can raise LDL-C (though not apoB); this is not seen with pure EPA (icosapent ethyl).
Overall, the risks for most patients are limited to minor GI/taste effects (“fishy taste”). However, caution should be taken for patients are at significant risk for development of atrial fibrillation (very small increase at ≥4000 mg/day) and in patients who are on anti-coagulation. However, the FDA has stated that fish oil at <3000mg/day is unlikely to cause any significant bleeding. Of note, DHA products may modestly raise LDL-C.
Where can I purchase Omega-3?
If you’d like to purchase omega-3 fatty acids, please visit the affiliate link below.
This product linked is dosed at 1780mg per capsule (with 1300mg EPA), therefore 1 capsule daily would be sufficient per dosing guidelines.
As a disclaimer, qualified purchases will go towards to an Amazon Associate account which in turn helps to keep this website going. Thank you!
affiliate link
Sources
Efficacy and Safety of N-3 Fatty Acids Supplementation on Depression: A Systematic Review and Dose-Response Meta-Analysis of Randomised Controlled Trials. The British Journal of Nutrition. 2024. Norouziasl R, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S.
Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids on Reducing Anxiety and/or Depression in Adults; A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2023. Kelaiditis CF, Gibson EL, Dyall SC.
Management of Major Depressive Disorder (MDD) (2022). Department of Veterans Affairs. 2022. Rhanda Brockington DNP FNP-BC, Andrew Buelt DO, Vincent Capaldi MD MSc FAPA FACP, et al.
Omega-3 Fatty Acid Supplementation for Depression in Children and Adolescents. The Cochrane Database of Systematic Reviews. 2024. Campisi SC, Zasowski C, Bradley-Ridout G, et al.
Nutrition and Prevention of Cognitive Impairment. The Lancet. Neurology. 2018. Scarmeas N, Anastasiou CA, Yannakoulia M.
Omega-3 Fatty Acids for Depression in Adults. The Cochrane Database of Systematic Reviews. 2021. Appleton KM, Voyias PD, Sallis HM, et al.
Omega-3 Polyunsaturated Fatty Acids Suppress the Inflammatory Responses of Lipopolysaccharide-Stimulated Mouse Microglia by Activating SIRT1 Pathways. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids. 2017. Inoue T, Tanaka M, Masuda S, et al.
Immunomodulation of Microglia by Docosahexaenoic Acid and Eicosapentaenoic Acid. Current Opinion in Clinical Nutrition and Metabolic Care. 2012. Hjorth E, Freund-Levi Y.
Impairment of DHA Synthesis Alters the Expression of Neuronal Plasticity Markers and the Brain Inflammatory Status in Mice. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2020. Talamonti E, Sasso V, To H, et al.
Experimental Evidence of ω ‐3 Polyunsaturated Fatty Acid Modulation of Inflammatory Cytokines and Bioactive Lipid Mediators: Their Potential Role in Inflammatory, Neurodegenerative, and Neoplastic Diseases. BioMed Research International. 2013. Calviello G, Su HM, Weylandt KH, et al.
Omega-3 Fatty Acids and Cognitive Function. Current Opinion in Lipidology. 2023. Welty FK.
Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition. 2023. Chang JP, Tseng PT, Zeng BS, et al.
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar. Journal of the American College of Cardiology. 2021. Weinberg RL, Brook RD, Rubenfire M, Eagle KA.
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.
Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Journal of the American Heart Association. 2024. Javaid M, Kadhim K, Bawamia B, et al.
Impact of health and lifestyle food supplements on periodontal tissues and health.
Periodontology 2000. 2022. Spahr A, Divnic-Resnik T.
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases.
Journal of the American College of Cardiology. 2009. Lavie CJ, Milani RV, Mehra MR, Ventura HO.
Effects of Omega-3 Fatty Acid Supplementation on Cigarette Craving and Oxidative Stress Index in Heavy-Smoker Males: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.
Journal of Psychopharmacology. 2018. Sadeghi-Ardekani K, Haghighi M, Zarrin R.
Effects of Omega-3 Fatty Acids on Tobacco Craving in Cigarette Smokers: A Double-Blind, Randomized, Placebo-Controlled Pilot Study. Journal of Psychopharmacology. 2014. Rabinovitz S.
Treatment for Tobacco Smoking: A New Alternative?. Medical Hypotheses. 2012. Zaparoli JX, Galduróz JC.
Omega-3 Fatty Acids Prevent Nicotine Withdrawal-Induced Exacerbation of Anxiety and Depression by Affecting Oxidative Stress Balance, Inflammatory Response, BDNF and Serotonin Metabolism in Rats. European Journal of Pharmacology. 2023. Amiry GY, Haidary M, Azhdari-Zarmehri H, Beheshti F, Ahmadi-Soleimani SM.
Omega-3 Fatty Acids Prevent Nicotine Withdrawal-Induced Impairment of Learning and Memory via Affecting Oxidative Status, Inflammatory Response, Cholinergic Activity, BDNF and Amyloid-B in Rat Hippocampal Tissues. Life Sciences. 2023. Ahmadi-Soleimani SM, Amiry GY, Khordad E, Masoudi M, Beheshti F.